Al Tamimi & Company Advised China Medical System Holdings Ltd On SGX Secondary Listing

Al Tamimi & Company advised China Medical System Holdings Ltd on SGX secondary listing

Al Tamimi & Company has recently advised China Medical System Holdings Ltd (CMS) on its secondary listing on the Singapore Exchange Main Board (SGX) under stock code 8A8.

CMS, a leading Chinese pharmaceutical group listed on the Hong Kong Stock Exchange since 2010, pursued this secondary listing to strengthen its capital base, enhance liquidity, and broaden its investor profile across the Asia-Pacific region. The listing reflects an estimated market capitalisation of SGD 4.7 billion (as of 15 July 2025).

Al Tamimi & Company advised on UAE legal requirements and conducted comprehensive due diligence on CMS’s UAE subsidiaries to ensure compliance with local laws and SGX disclosure obligations, facilitating a smooth and timely listing process.

The Al Tamimi & Company team was led by Andrew Tarbuck and Alyzeh Zahid, supported by Jingzhuo Wu and Ahmad El Chami, with further contributions from Samer Qudah, Masood Khan, Samir Kantaria, Jennifer Leader Green, Andrew Thomson, Tessa Crawford, Serena McLeod (née Stangroom), Ena Tahric, Shiraz Khan, Sahid Daud, Saif Abdulelah, and Tammam Jazmati.

If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at [email protected] or call us on +91 8879634922.